IL132303A0 - Gnrh antagonists being modified in positions 5 and 6 - Google Patents

Gnrh antagonists being modified in positions 5 and 6

Info

Publication number
IL132303A0
IL132303A0 IL13230398A IL13230398A IL132303A0 IL 132303 A0 IL132303 A0 IL 132303A0 IL 13230398 A IL13230398 A IL 13230398A IL 13230398 A IL13230398 A IL 13230398A IL 132303 A0 IL132303 A0 IL 132303A0
Authority
IL
Israel
Prior art keywords
modified
positions
gnrh antagonists
gnrh
antagonists
Prior art date
Application number
IL13230398A
Other languages
English (en)
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25273352&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL132303(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of IL132303A0 publication Critical patent/IL132303A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/11—Gonadotropin; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL13230398A 1997-04-11 1998-04-13 Gnrh antagonists being modified in positions 5 and 6 IL132303A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/837,042 US5925730A (en) 1997-04-11 1997-04-11 GnRH antagonists
PCT/US1998/007438 WO1998046634A1 (en) 1997-04-11 1998-04-13 GnRH ANTAGONISTS BEING MODIFIED IN POSITIONS 5 AND 6

Publications (1)

Publication Number Publication Date
IL132303A0 true IL132303A0 (en) 2001-03-19

Family

ID=25273352

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13230398A IL132303A0 (en) 1997-04-11 1998-04-13 Gnrh antagonists being modified in positions 5 and 6

Country Status (37)

Country Link
US (2) US5925730A (no)
EP (1) EP1003774B1 (no)
JP (2) JP4249806B2 (no)
KR (1) KR100519421B1 (no)
CN (1) CN1230442C (no)
AR (1) AR011217A1 (no)
AT (1) ATE319736T1 (no)
AU (1) AU728642B2 (no)
BR (1) BR9808523B1 (no)
CA (1) CA2286190C (no)
CY (2) CY1108063T1 (no)
CZ (1) CZ299097B6 (no)
DE (2) DE69833751T2 (no)
DK (1) DK1003774T3 (no)
EE (1) EE03974B1 (no)
ES (1) ES2260833T3 (no)
FR (1) FR09C0028I2 (no)
HK (1) HK1025104A1 (no)
HR (1) HRP980197B1 (no)
HU (1) HU224836B1 (no)
IL (1) IL132303A0 (no)
LU (1) LU91585I2 (no)
MY (1) MY114811A (no)
NL (1) NL300395I2 (no)
NO (2) NO324991B1 (no)
NZ (1) NZ500142A (no)
PL (1) PL194509B1 (no)
PT (1) PT1003774E (no)
RU (1) RU2199549C2 (no)
SI (1) SI1003774T1 (no)
SK (1) SK285381B6 (no)
TR (1) TR199902956T2 (no)
TW (1) TW505658B (no)
UA (1) UA58547C2 (no)
UY (1) UY24958A1 (no)
WO (1) WO1998046634A1 (no)
ZA (1) ZA983062B (no)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828415B2 (en) * 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
US5925730A (en) * 1997-04-11 1999-07-20 Ferring Bv GnRH antagonists
WO1999026964A1 (en) * 1997-11-20 1999-06-03 Ortho-Mcneil Pharmaceutical, Inc. LIQUID PHASE PROCESS FOR THE PREPARATION OF GnRH PEPTIDES
US8119159B2 (en) * 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
GB0117057D0 (en) * 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
IL147138A0 (en) * 2001-12-17 2002-08-14 Yeda Res & Dev Methods of and pharmaceutical compositions for modulating cell adhesion, migration and extravasation
DE20321887U1 (de) 2003-11-10 2012-01-20 Allergan, Inc. Arzneimittel umfassend niedrige Dosierungen von Desmopressin
EP2322194A2 (en) 2003-11-10 2011-05-18 Reprise Biopharmaceutics, LLC Pharmaceutical compositions including low dosages of desmopressin
CN101037472B (zh) * 2006-03-14 2013-03-27 中国人民解放军军事医学科学院毒物药物研究所 具有低组胺释放作用的促黄体生成素释放激素拮抗剂
BRPI0710503A2 (pt) * 2006-04-07 2011-08-16 Merrion Res Iii Ltd uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral
TWI539959B (zh) * 2008-02-11 2016-07-01 菲瑞茵國際中心股份有限公司 治療轉移階段攝護腺癌的方法
CN102046192B (zh) * 2008-05-07 2014-11-19 默里昂研究Ⅲ有限公司 GnRH相关化合物的组合物及制备方法
WO2010099255A1 (en) * 2009-02-25 2010-09-02 Merrion Research Iii Limited Composition and drug delivery of bisphosphonates
US8828938B2 (en) * 2009-04-24 2014-09-09 Polypeptide Laboratories A/S Method for the manufacture of degarelix
EP2424503B1 (en) * 2009-05-01 2017-07-05 Ferring BV Composition for the treatment of prostate cancer
TW201043221A (en) * 2009-05-06 2010-12-16 Ferring Int Ct Sa Kit and method for preparation of a Degarelix solution
US20110039787A1 (en) 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
WO2011066386A1 (en) 2009-11-25 2011-06-03 Novetide, Ltd. Process for production of degarelix
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
US9089484B2 (en) * 2010-03-26 2015-07-28 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
EP2447276A1 (en) * 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
ES2617336T3 (es) 2010-10-27 2017-06-16 Ferring B.V. Procedimiento para la fabricación de degarelix y sus productos intermedios
JP6100699B2 (ja) 2010-12-22 2017-03-22 ザ ソルク インスティテュート フォー バイオロジカル スタディーズ 環状ｃｒｆアンタゴニストペプチド及びその薬学的に許容される塩
CN103476419A (zh) 2011-01-07 2013-12-25 梅里翁第三研究有限公司 口服投药的含铁药物组合物
JO3755B1 (ar) 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
WO2013104745A1 (en) 2012-01-13 2013-07-18 Ferring Bv Pharmaceutical composition
SG11201407679PA (en) 2012-06-01 2014-12-30 Ferring Bv Manufacture of degarelix
CN107205948B (zh) 2015-01-29 2021-12-14 诺和诺德股份有限公司 包含glp-1激动剂和肠溶衣的片剂
US11168114B2 (en) 2015-12-17 2021-11-09 Fresenius Kabi iPSUM S.r.l Process for the manufacture of degarelix and its intermediates
CN107778355B (zh) * 2016-08-25 2021-04-20 成都圣诺生物制药有限公司 一种合成西曲瑞克的方法
WO2019110688A1 (en) 2017-12-05 2019-06-13 Ferring B.V. A composition comprising degarelix for use in the treatment of breast cancer
EP4004001A4 (en) 2019-07-29 2023-08-30 Sunshine Lake Pharma Co., Ltd. SUBSTITUTED PYRIMIDINEONE COMPOUNDS AND USES THEREOF
US11332495B2 (en) 2019-09-21 2022-05-17 RK Pharma Solutions LLC Process for the preparation of Degarelix acetate and Degarelix acetate-mannitol premix
CN114456236A (zh) * 2020-11-09 2022-05-10 深圳市健翔生物制药有限公司 一种地加瑞克乙酰化杂质的制备方法
WO2023072284A1 (zh) 2021-11-01 2023-05-04 山东绿叶制药有限公司 促性腺素释放激素拮抗剂及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4547370A (en) * 1983-11-29 1985-10-15 The Salk Institute For Biological Studies GnRH Antagonists
US4508921A (en) * 1984-06-28 1985-04-02 Merck & Co., Inc. Process for preparation of alpha-alkyl amino acids
US4866160A (en) * 1985-04-09 1989-09-12 The Administrators Of The Tulane Educational Fund Therapeutic decapeptides
US5073624A (en) * 1985-04-09 1991-12-17 Administrators Of The Tulane Educational Fund Therapeutic decapeptides
US4800191A (en) * 1987-07-17 1989-01-24 Schally Andrew Victor LHRH antagonists
US4935491A (en) * 1987-08-24 1990-06-19 Board Of Regents, The University Of Texas System Effective antagonists of the luteinizing hormone releasing hormone which release negligible histamine
US5171835A (en) * 1988-10-21 1992-12-15 The Administrators Of The Tulane Educational Fund LHRH antagonists
US5296468A (en) * 1989-10-30 1994-03-22 The Salk Institute For Biological Studies GnRH analogs
DE69214818T2 (de) * 1991-04-25 1997-02-27 Romano S.-Cergue Deghenghi LHRH-Antagonisten
WO1994014841A1 (en) * 1992-12-18 1994-07-07 Abbott Laboratories Lhrh antagonists having modified aminoacyl residues at postions 5 and 6
IL108509A0 (en) * 1993-02-22 1994-05-30 Salk Inst For Biological Studi GnRH antagonist peptides
US5506207A (en) * 1994-03-18 1996-04-09 The Salk Institute For Biological Studies GNRH antagonists XIII
US5843901A (en) * 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
US5925730A (en) * 1997-04-11 1999-07-20 Ferring Bv GnRH antagonists

Also Published As

Publication number Publication date
JP4249806B2 (ja) 2009-04-08
JP3645255B1 (ja) 2005-05-11
UA58547C2 (uk) 2003-08-15
BR9808523A (pt) 2000-05-23
NZ500142A (en) 2001-10-26
US6214798B1 (en) 2001-04-10
EE9900479A (et) 2000-06-15
CZ358699A3 (cs) 2000-06-14
NO994906L (no) 1999-12-13
PT1003774E (pt) 2006-05-31
EP1003774B1 (en) 2006-03-08
TR199902956T2 (xx) 2000-08-21
CN1230442C (zh) 2005-12-07
NO2009016I1 (no) 2009-08-10
UY24958A1 (es) 2001-03-16
HRP980197B1 (en) 2002-08-31
CY1108063T1 (el) 2012-01-25
SI1003774T1 (sl) 2006-08-31
HUP0002704A3 (en) 2003-08-28
SK139699A3 (en) 2000-11-07
CA2286190C (en) 2007-01-09
DE122009000033I2 (de) 2011-07-21
CY2009008I2 (el) 2012-01-25
NO2009016I2 (no) 2014-08-25
NO324991B1 (no) 2008-01-14
KR100519421B1 (ko) 2005-10-06
FR09C0028I2 (fr) 2010-06-11
ATE319736T1 (de) 2006-03-15
PL336213A1 (en) 2000-06-05
EE03974B1 (et) 2003-02-17
ES2260833T3 (es) 2006-11-01
DE69833751T2 (de) 2006-11-09
ZA983062B (en) 1998-10-20
SK285381B6 (sk) 2006-12-07
HRP980197A2 (en) 1999-02-28
NO994906D0 (no) 1999-10-08
CA2286190A1 (en) 1998-10-22
PL194509B1 (pl) 2007-06-29
FR09C0028I1 (no) 2009-09-25
TW505658B (en) 2002-10-11
DK1003774T3 (da) 2006-07-03
JP2001523229A (ja) 2001-11-20
EP1003774A1 (en) 2000-05-31
HUP0002704A2 (hu) 2000-12-28
RU2199549C2 (ru) 2003-02-27
CN1259959A (zh) 2000-07-12
AU728642B2 (en) 2001-01-11
KR20010006233A (ko) 2001-01-26
HK1025104A1 (en) 2000-11-03
CY2009008I1 (el) 2012-01-25
AU6969898A (en) 1998-11-11
LU91585I2 (fr) 2009-09-17
DE122009000033I1 (de) 2009-09-17
NL300395I1 (nl) 2009-09-01
BR9808523B1 (pt) 2010-02-09
CZ299097B6 (cs) 2008-04-23
AR011217A1 (es) 2000-08-02
MY114811A (en) 2003-01-31
NL300395I2 (nl) 2010-01-04
DE69833751D1 (de) 2006-05-04
JP2005120101A (ja) 2005-05-12
HU224836B1 (en) 2006-03-28
WO1998046634A1 (en) 1998-10-22
US5925730A (en) 1999-07-20

Similar Documents

Publication Publication Date Title
HUP0002704A3 (en) Gnrh antagonists being modified in positions 5 and 6
HUP0102535A3 (en) Cd19xcd3 specific polypeptides and uses thereof
EP1021185A4 (en) DIHYDROPYRIMIDINE AND ITS USES.
PL337781A1 (en) Antagonists and reverse antagonists of glucogene
EP0894807A4 (en) GPIb lipid complex and its applications
IL131368A0 (en) Antipathogenic synthetic peptides and compositions comprising them
ZA9811086B (en) Delivery devices and their use
EP0973389A4 (en) NITROGEN-CONTAINING OXYALKYLENE ESTERS AND USES THEREOF
HK1033653A1 (en) Synergistic composition and use thereof
HUP9700446A3 (en) Oilsuspension-concentrate and using thereof
IL127319A0 (en) Lactoferrin variants and uses thereof
GB9806806D0 (en) Peptides and uses thereof
EP0948323A4 (en) PROTEASE-ACTIVATED RECEPTOR 3 AND THEIR USE
PL329351A1 (en) Piperidines and pyrolydines
GB9704349D0 (en) Levobupivacaine and its use
PL331523A1 (en) Azolotrizines and azolopyrimidines
GB9701374D0 (en) Purinergic agonists and antagonists
GB9622905D0 (en) Dispersing agents and their use
EP0998578A4 (en) SEL-10 AND USES OF SEL-10
GB9704370D0 (en) Levobupivacaine and its use
PL307138A1 (en) Amyline antagonists and agonists
PL341293A1 (en) Beta-lypothropin and application thereof
GB9722023D0 (en) Levobupivacaine and its use
GB9722392D0 (en) Composition and use
GB9828036D0 (en) Oligopeptides and their use

Legal Events

Date Code Title Description
KB Patent renewed
EXTF Application for patent extension filed
KB Patent renewed
PEL Intention of commissioner to extend period of protection

Free format text: PRODUCT NAME: DEGARELIX

Extension date: 20190706

EXTN Extension order renewed
EXTN Extension order renewed